Cimemoxin

Cimemoxin

Cimemoxin

Chemical compound

Cimemoxin (INN), or cyclohexylmethylhydrazine, is a hydrazine monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.[1]

Quick Facts Clinical data, ATC code ...

Synthesis

It possesses 50 times the relative activity of iproniazid and 25x nialamide (see patent).

Synthesis:[2][3][4]

3-Cyclohexene-1-carbaldehyde [100-50-5] (aka 1,2,3,6-Tetrahydrobenzaldehyde) is reacted with N-acetylhydrazine to give the hydrazone, which is reduced by catalytic hydrogenation. The acetyl group is removed by acid hydrolysis.

See also

References

  1. [1]
    World Health Organization (2011). "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Retrieved 2012-05-20.
  2. [2]
    Boissier JR, Ratouis R, Dumont C, Lesbros J (1966). "Synthesis of new monoamine oxidase inhibitors". Chimica Therapeutica (5–6): 320–326.
  3. [3]
    FR 1405420, Boissier JR, Ratouis R, "ouvelle hydrazine et ses sels et procédé de préparation", issued 1965, assigned to Soc Ind Fab Antibiotiques Sifa.
  4. [4]
    GB 1102228, "N-hexahydrobenzyl hydrazine and its salts and process for preparation thereof", issued 1968, assigned to Soc Ind Fab Antibiotiques Sifa.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Cimemoxin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.